CONCORD NEWS IN YOUR INBOX: SIGN UP HERE

Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Can-Fite Biopharma Ltd American Depositary Shares (NY:CANF)

2.990 +0.070 (+2.40%)
Streaming Delayed Price Updated: 1:53 PM EDT, Apr 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Why Is Liver Cancer Focused Can-Fite BioPharma Stock Trading Higher Today? ↗
Can-Fite BioPharma Ltd (NYSE: CANF) announced that a patient who participated in the Phase 2 Liver Cancer Study and was treated with namodenoson had a complete response and overall survival of  
Via Benzinga
News headline image
Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Recap: Can Fite Biofarma Q1 Earnings ↗
 
Via Benzinga
News headline image
Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page 
Via Benzinga
News headline image
Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Present at the Emerging Growth Conference on July 13, 2023
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers 
Via MarketBeat
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
It's time for another dive into the biggest pre-market stock movers as we see what's moving the market on Thursday morning! 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
From Can-Fite BioPharma Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article